No Picture
News

Chiesi Global Rare Diseases Announces Approval of FERRIPROX™ MR Deferiprone Extended-Release Tablets in Canada

New formulation allows twice-daily dosing in patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate, or sickle cell disease or other anemias. BOSTON, March 31, 2023 /PRNewswire/ — Chiesi Global Rare Diseases, a business unit of… Click here to view original post… […]

No Picture
News

IMV Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.–(BUSINESS WIRE)—- $IMV #CancerVaccine–IMV Inc. (“IMV” or the “Company”) (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced that on March 29, 2023, IMV Inc. (the “Company”)… Click here to view original post… […]

No Picture
News

Adiso Therapeutics Announces Participation at Healthruption, Goldman Sachs Second Annual Healthcare Disruption Conference

CONCORD, Mass., March 31, 2023 /PRNewswire/ — Adiso Therapeutics, Inc., a clinical-stage biotechnology company committed to creating medicines that treat inflammatory diseases and improve the lives of patients and their families, today announced that Scott Megaffin, Chief Executive… Click here to view original post… […]

No Picture
News

A shot in the arm

Researchers develop new, patient-friendly hydrogel platform for administering lifesaving biologics. Click here to view original post… […]

No Picture
News

Jim Mullen scours private equity deals amid biotech winter; Ex-AbbVie medical chief succeeds Briggs Morrison at Syndax

Jim Mullen is in, by his count, his third or fourth “long, cold winter in biotech investing.” But that’s not stopping the ex-Biogen CEO from finding flickers of light. Jim Mullen Earlier this week, private equity player Advent International announced that Mullen had joined as… Click here to view original post… […]